Citations 1
IgM myeloma: A multicenter retrospective study of 134 patients
Castillo, Jorge J. , Brožová, Lucie , Czepiel, Jacek , Dávila, Julio , Ghobrial, Irene M. , Gozzetti, Alessandro , Gustine, Joshua , Hájek, Roman , Jayabalan, David , Laubach, Jacob P. , Lewicka, Barbara , Maisnar, Vladimír , Manasanch, Elisabet E. , Moreau, Philippe , Nahi, Hareth , Niesvizky, Rubén, Paba‐Prada, Claudia E., Pika, Tomáš, Pour, Luděk , Reagan, John L. , Richardson, Paul G. , Shah, Jatin J., Špıčka, Ivan , Vij, Ravi , Jurczyszyn, Artur , Crusoé, Edvan de Queiroz , Dispenzieri, Angela , Eveillard, Marion , Fiala, Mark A. , Hungria, Vânia , Jarkovský, Jiří , Morgan, Elizabeth A. , Richardson, Paul Gerard Guy , Waszczuk‐Gajda, Anna , Gertz, Morie A. , Hajek, Roman , Moreau, Philippe , Castillo, Jorge J , Ghobrial, Irene M , Gozzetti, Alessandro , Nahi, Hareth
American Journal of Hematology | April 6, 2017 | Volume: 92 | Issue: 8 | Pages: 746-751
AbstractIgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.